Immune Tolerance Network (UM1 Clinical Trial Required)
Limited submission
NIH funds continuation of the Immune Tolerance Network to develop tolerogenic therapies through clinical trials and mechanistic studies in allergy, asthma, autoimmunity, and transplantation.
Funder: National Institutes of Health
Due Dates: January 29, 2027 (Application, 5:00 p.m. applicant organization’s local time)
Funding Amounts: $27 million committed for one award in FY 2028; budgets expected not to exceed $23 million annually in direct costs; seven-year project
Summary: Supports continuation of the Immune Tolerance Network to develop tolerogenic therapies through clinical trials and integrated mechanistic studies.
Key Information: Only one application per institution is allowed, and proposals must cover all three clinical areas.
Description
The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, supports continuation of the Immune Tolerance Network (ITN) through a UM1 cooperative agreement. The Network develops therapies that block harmful immune responses while preserving protective immunity. Its work spans allergic diseases and asthma, autoimmune diseases, and immune-mediated consequences of transplantation.
This opportunity supports a cross-disciplinary consortium responsible for designing, conducting, and sharing results from clinical trials with integrated mechanistic studies. The Network must integrate leadership, clinical operations, core laboratories, and bioinformatics. Research priorities include durable remission, novel allergen immunotherapy, restoration of immune homeostasis, donor-specific tolerance, improved graft survival, and biomarkers predicting allograft tolerance. NIAID will have substantial scientific and programmatic involvement and provide supporting clinical research resources.
